This proposal aimed to interrogate at single cell level the tumor microenvironment of CAR-T and TCE treated MM patients to elucidate the immune-mediated causes of resistance, identify potential means to reverse tolerance, and study how genomics might predict which patients should benefit the most from T-cell based therapies.
The project focuses on using the anticancer peptide PNC-27, which targets the p53 pathway, as a potential therapeutic approach for multiple myeloma (MM). While MM with high-risk features like TP53 deletion has poorer outcomes, PNC-27 has shown promising results in cancer cells, including MM, by inducing cell death. Despite the absence of MDM2 on MM … Continued
The project aims to investigate GCK as a therapeutic target for RAS-mutated multiple myeloma (MM), where current treatments are lacking. RAS pathway mutations are common in MM, driving disease progression, yet no RAS inhibitors are clinically available. GCK, a key player in B cell differentiation, has been found critical for MM cell survival and growth, … Continued
The project aims to explore APOBECs as potential therapeutic targets in multiple myeloma (MM). Aim 1 focuses on identifying druggable APOBEC targets by modulating their expression in MM cells and assessing their impact on cellular characteristics. This involves genetic manipulations and functional assays to determine downstream pathways affected by APOBEC activation. Aim 2 investigates the … Continued
Multiple myeloma (MM) is a bone marrow-resident hematologic malignancy of plasma cells and the second most diagnosed blood cancer, after non-Hodgkin lymphoma. Despite the development of myeloma-targeted immunotherapies, MM remains largely incurable. The objective of this research is to evaluate tissue factor (TF, also known as coagulation factor III and CD142) as a new target … Continued
The study aims to enhance the efficacy of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM) by engineering CAR-T cells to secrete interleukin-12 (IL-12) and an anti-IL-6 single domain antibody (sdAb). While current CAR-T therapies targeting BCMA show promising response rates, median progression-free survival remains short, indicating the need for improved strategies. The … Continued
The rationale of this research translational project has been to investigate the role of glutamine (Gln) and glutamate metabolism as possible new diagnostic tools for MM bone disease in MM patients. The aims of the project were: -Firstly, to check how the alteration of Gln metabolisms induced by MM cells and consequently the Gln addicted … Continued
This research identifies MM-specific bone marrow mesenchymal stromal cells (iMSC) as crucial components of the pro-tumor microenvironment in Multiple Myeloma (MM). These iMSCs support MM cell survival and proliferation and are associated with bone marrow inflammation. Despite successful induction treatment, iMSC presence persists, potentially contributing to therapy resistance and relapse. The study aims to determine … Continued
This research aims to target mitochondrial vulnerabilities in multiple myeloma (MM) by focusing on ClpP, a mitochondrial protease highly expressed in MM cells. Leveraging ClpP’s importance for MM cell survival, the study seeks to understand its function and identify novel mitochondrial vulnerabilities. Using functional geno-proteomics and genetic screening, the research aims to achieve two main … Continued
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.
The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.
